Related Experiment Videos
Safety of imipenem/cilastatin in neurocritical care patients
Jason Hoffman1, Jason Trimble, Gretchen M Brophy
1Department of Pharmacy, Carilion Roanoke Memorial Hospital, Roanoke, VA, USA.
Background:
Infection in the intensive care unit (ICU) empirically requires broad-spectrum antibiotics. Imipenem/cilastatin, often reserved for more serious hospital-acquired infections, is thought to be associated with a higher risk of seizures than other penicillins and carbapenems. We sought to evaluate the safety of imipenem/cilastatin in the treatment of infections, including meningitis, in neurocritical care patients.
Methods:
Pertinent literature was identified through MEDLINE (1966-2007) using search terms imipenem, seizure, carbapenem, and meropenem. A review of the literature is presented.
Results:
Carbapenem antibiotics remain active against most Gram-positive and Gram-negative organisms, and are often used in critically ill patients. Drug-induced seizures are a rare but serious adverse effect, with carbapenems being one of the most common classes of antibiotics associated with seizures. Seizure rates in patients treated with imipenem/cilastatin and meropenem are similar. One small pediatric study of 21 patients showed a high incidence of seizures and is often cited as the reason imipenem should not be used in meningitis. However, many studies noting seizures with both meropenem and imipenem/cilastatin attribute this to patients with lower body weight, elderly, or those with impaired renal function.
Conclusions:
When dosed appropriately, imipenem/cilastatin may be used to treat serious infections in critically ill patients with central nervous system (CNS) disorders or injury with minimal seizure risk. Imipenem/cilastatin safety data is lacking for meningitis and cautious use is warranted.
Insights
Imipenem/cilastatin can be safely used for serious infections in neurocritical care patients when dosed correctly. While seizures are a risk with carbapenems, imipenem/cilastatin has a low risk in this population.
Area of Science:
- Infectious Diseases
- Neurocritical Care
- Pharmacology
Background:
- Intensive care unit (ICU) infections necessitate broad-spectrum antibiotics.
- Imipenem/cilastatin, a potent antibiotic, is associated with a potential increased risk of seizures compared to other penicillins and carbapenems.
- Neurocritical care patients with CNS disorders or injuries often require aggressive infection management.
Purpose of the Study:
- To evaluate the safety of imipenem/cilastatin in treating infections, including meningitis, within neurocritical care settings.
- To assess the risk of seizures associated with imipenem/cilastatin use in this vulnerable patient population.
Main Methods:
- A comprehensive literature review was conducted using MEDLINE.
- Search terms included imipenem, seizure, carbapenem, and meropenem.
- The review synthesized findings on carbapenem antibiotic use and associated adverse events.
Main Results:
- Carbapenems are effective against a wide range of pathogens and frequently used in critically ill patients.
- Seizures are a rare but serious adverse effect linked to carbapenems.
- Seizure rates for imipenem/cilastatin and meropenem are comparable, with risk factors including low body weight, advanced age, and renal impairment.
Conclusions:
- Appropriate dosing of imipenem/cilastatin allows for safe use in critically ill patients with CNS conditions, with minimal seizure risk.
- While generally safe, specific safety data for imipenem/cilastatin in meningitis is limited, warranting cautious administration.
Related Concept Videos
Endocarditis IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Coronary Syndrome IV: Interprofessional Care
Aneurysm IV: Nursing Management
Cardiac Catheterization I: Pre-Procedure Overview
Pericarditis IV: Nursing Management